物理数据管道自愈报告 • 编译时间 2026-06-12 00:00:00 UTC
评估 V2 Apex 定向免疫原 DV201P-RNA 和 DV202B1-RNA 在未感染 HIV 的成年参与者中的安全性和免疫原性的临床试验 主办方：国家过敏和传染病研究所 (NIAID) 描述：这是一项 1 期、多中心、开放标签、剂量递增、首次人体 (FIH) 试验，旨在评估 DV201P-RNA 和 DV202B1-RNA 的安全性和免疫原性，这些免疫原旨在诱导 HIV-1 包膜 (Env) V2 apex 特异性广泛中和抗体 (V2 apex bnAbs) 这两种疫苗均由封装在脂质纳米颗粒 (LNP) 中的修饰 mRNA 组成，当在细胞中翻译时，会产生 HIV-1 Env gp150 跨膜三聚体 该试验将招募没有艾滋病毒且整体健康状况良好的成年志愿者。 病症：艾滋病毒
六价流感 mRNA 疫苗对 50 岁及以上成人参与者的安全性和免疫原性研究 赞助商：赛诺菲巴斯德，赛诺菲公司 描述：本研究的目的是评估单次肌肉注射不同配方的六价流感信使核糖核酸 (mRNA) 疫苗的安全性和免疫原性，该疫苗由不同剂量水平的三价 (TIV) mRNA 血凝素 (HA) 与 TIV mRNA 神经氨酸酶 (NA) 组合组成，与活性对照（（Fluzone 标准剂量四价流感疫苗 (QIV-SD) 或 Fluzone）相比） 50 岁及以上成人高剂量四价流感疫苗 (QIV-HD)。 条件：流感、健康志愿者
标题：优化用于mRNA递送的基于C14120的脂质纳米颗粒：编辑评论。期刊： Mol Ther Nucleic Acids.作者： Fung V, Argenti C, Magaw M, Fenton O.摘要：
发表在ACS Sens上的具有里程碑意义的论文显示： Modular CRISPR-Cas12a-Activated Gold Nanoparticle Assay for Rapid Visual Detection of Hepatocellular Carcinoma-Related miRNAs。
吉利德和默克的最新试验成功和失败。摘要：阿斯利康的GLP-1药丸，葛兰素史克以106亿美元收购癌症创业公司，以及来自The Readout的更多生物技术新闻
城市银行近1亿美元用于下一代RNAi药物 摘要： City由Alnylam长期首席执行官John Maraganore共同创立，将凝血障碍药物引入早期人体测试 Stargardt病的实验性疗法可能很快就会出现。
评估 V2 Apex 定向免疫原 DV201P-RNA 和 DV202B1-RNA 在未感染 HIV 的成年参与者中的安全性和免疫原性的临床试验 主办方：国家过敏和传染病研究所 (NIAID) 描述：这是一项 1 期、多中心、开放标签、剂量递增、首次人体 (FIH) 试验，旨在评估 DV201P-RNA 和 DV202B1-RNA 的安全性和免疫原性，这些免疫原旨在诱导 HIV-1 包膜 (Env) V2 apex 特异性广泛中和抗体 (V2 apex bnAbs) 这两种疫苗均由封装在脂质纳米颗粒 (LNP) 中的修饰 mRNA 组成，当在细胞中翻译时，会产生 HIV-1 Env gp150 跨膜三聚体 该试验将招募没有艾滋病毒且整体健康状况良好的成年志愿者。 病症：艾滋病毒
六价流感 mRNA 疫苗对 50 岁及以上成人参与者的安全性和免疫原性研究 赞助商：赛诺菲巴斯德，赛诺菲公司 描述：本研究的目的是评估单次肌肉注射不同配方的六价流感信使核糖核酸 (mRNA) 疫苗的安全性和免疫原性，该疫苗由不同剂量水平的三价 (TIV) mRNA 血凝素 (HA) 与 TIV mRNA 神经氨酸酶 (NA) 组合组成，与活性对照（（Fluzone 标准剂量四价流感疫苗 (QIV-SD) 或 Fluzone）相比） 50 岁及以上成人高剂量四价流感疫苗 (QIV-HD)。 条件：流感、健康志愿者
隐形初创公司Treeline计划进行反向合并 摘要：在 Loxo Oncology 前首席执行官 Josh Bilenker 的领导下，这家初创公司目前拥有三种处于早期测试阶段的抗癌药物，还有更多药物紧随其后。
Nat Commun ：爆红减重针再破圈 ！司美格鲁肽或可放缓人体表观遗传衰老 ！.来源报道正文:
STAT + ：美国许多药品短缺 仍然是一个“系统性”问题，一项新的分析发现 摘要：美国处方药短缺数量 去年下降了23% ，但一项新的分析发现，药品供应短缺的其他令人不安的迹象。
无。总结：通过一对2期读数，阿斯利康正在定位自己，以潜在地占领口服GLP-1市场的一部分。接下来，它的电毛囊正进入关键研究领域。
无 摘要： FDA已扩大了辉瑞Hympavzi的标签，现在包括患有血友病A或B的6岁及以上患者 新的扩展涵盖所有6岁及以上的患者，无论其抑制剂状态如何 新的NOD也为那些已经开发出抑制剂的12岁及以上的人打开了治疗的大门。
无。摘要：随着肥胖症的普及，礼来正在推动其新推出的Foundayo （ orforglipron ）突破2型糖尿病。
无。总结：在其2b期临床试验未达到主要和关键次要有效性终点后， BIAL已停止在帕金森病患者亚群中的发展。
ADA ‘26 ：礼来的主导地位，辉瑞的“基础”药物和罗氏的“me-too”选项 摘要：在一次减肥药物的大型会议上，礼来公司的“三重 G”疗法树立了新标准，因为其他竞争疗法仍存在挥之不去的疑虑。
不断上涨的医疗保健成本似乎是不可避免的。发布时间： 2026年6月11日，星期四17:53:09 +0000。摘要：我们首次看到了明年医疗保健费用的走向。 根据对27个健康计划的精算师的调查，涵盖了交易所的雇主和个人
Camurus针对肢端肥大症药物的第二个CRL ； Teva详细介绍了裁员情况。发布时间： 2026年6月11日，星期四14:45:20 +0000。摘要：此外，有关药品短缺报告和Axplora的新闻： 🛑 Camurus被第二次CRL击中：由于第三方制造商的问题，药物CAM2029在肢端肥大症中被拒绝。...
吉利德和默克的最新试验成功和失败。摘要：阿斯利康的GLP-1药丸，葛兰素史克以106亿美元收购癌症创业公司，以及来自The Readout的更多生物技术新闻
无 摘要：随着许可和并购交易的数量和价值持续增加，生物技术行业的蓬勃发展使其能够克服不利因素并在 2026 年之前保持增长势头 New 首次公开募股（IPO）s and the recovery of venture capital funding are helping, as well.
无。摘要：在肥胖生物技术公司Kailera Therapeutics获得该行业有史以来最大的首次公开募股（高达6.25亿美元）仅仅几个月后， Parabilis Medicines就扩大了自己的首次公开募股计划，有可能超越这一记录。
没有任何。摘要：礼来公司 (Eli Lilly) 已签署一项重磅协议，以高达 10 亿美元的生物资金从 AlzeCure Pharma 获得伽马分泌酶调节剂治疗阿尔茨海默病的许可。
无。摘要：瑞士医疗技术公司CeQur在一轮E轮融资中筹集了1亿美元($) ，用于其所谓的“最雄心勃勃的商业增长阶段”。
GSK 通过 11B 美元收购 Nuvalent 扩大癌症产品线 摘要：这家英国制药商今年的第三次收购使其获得了两种正在接受 FDA 审查的实验性肺癌药物，希望能够支持其特许经营权。
罗氏斥资 7 亿美元购买 Nurix 的蛋白质降解药物 摘要：此次合作的潜在价值高达 23 亿美元，押注的是能够消除“BTK”酶的药物将优于阻止其活性的现有药物。
无。摘要： Fierce Pharma将推出每周一次的Oral GLP-1 Tracker ，利用分析师的笔记和IQVIA数据来监测处方趋势和市场份额的变化，因为Novo Nordisk的Wegovy药丸和Eli Lilly的Foundayo竞相成为数百万人的首选口服减肥解决方案。
无 摘要：加拿大皇家银行资本市场 (RBC Capital Markets) 分析师 Trung Hyunh 表示，礼来公司 (Eli Lilly) 成为“ADA 的明显赢家”，他补充说，“该领域正变得越来越拥挤，但礼来公司 (Lilly) 正在扩大领先优势。”
Summit以“市场状况”为由撤回$ 5亿美元发行 发布时间： 2026年6月11日，星期四15:12:38 +0000 摘要：目前的生物技术环境显然可以支持行业创纪录的IPO ，同时阻碍筹集5亿美元的努力。 Summit Therapeutics放弃了5亿美元($)公开募股的计划，该公司在一份...
| 事件ID | 日期 | 事件类型 | 目标企业 | 技术模态 | 数据来源 | 完整数据链条 |
|---|---|---|---|---|---|---|
| ev-83ffe077 | 2026-06-12 | 专利布局 | Moderna | mRNA (信使RNA) | 欧洲PMC文献Europe PMC |
查看完整Payload{
"event_id": "ev-83ffe077",
"event_type": "patent",
"event_subtype": "application_filed",
"event_date": "2026-06-12",
"source_url": "https://europepmc.org/article/PMC/PMC13226814",
"source_type": "news",
"company_ids": [
"co-moderna"
],
"confidence": 0.9,
"raw_text_snippet": "Title: Optimizing C14120-based lipid nanoparticles for mRNA delivery: Editorial commentary. Journal: Mol Ther Nucleic Acids. Authors: Fung V, Argenti C, Magaw M, Fenton O.. Abstract: ",
"created_at": "2026-06-12T08:16:43.681517",
"payload": {
"claim_scope": "composition",
"patent_number": null,
"modality_id": "mo-mrna",
"delivery_id": "de-lnp"
},
"published_at": "2026-06-12",
"updated_at": "2026-06-12",
"ingested_at": "2026-06-12T08:16:43.681500Z",
"source": "https://europepmc.org/article/PMC/PMC13226814",
"timestamp": "2026-06-12T00:00:00Z",
"raw_text": "Title: Optimizing C14120-based lipid nanoparticles for mRNA delivery: Editorial commentary. Journal: Mol Ther Nucleic Acids. Authors: Fung V, Argenti C, Magaw M, Fenton O.. Abstract: ",
"strategic_tags": [
"lnp"
],
"signal_candidates": [],
"industry_impact": "low",
"evidence_type": "preclinical",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 1.6,
"quality_score": 0.675,
"company": "Moderna",
"modality": "mRNA",
"delivery_system": "LNP (lipid nanoparticles)",
"entities": {
"company_ids": [
"co-moderna"
],
"modality_ids": [
"mo-mrna"
],
"delivery_ids": [
"de-lnp"
],
"indication_ids": []
},
"decay_weight": 1.0,
"delta_days": 0
}
|
| ev-c000124d | 2026-06-12 | 专利布局 | Broad | RNA | FierceBiotechFierceBiotech |
查看完整Payload{
"event_id": "ev-c000124d",
"event_type": "patent",
"event_subtype": "application_filed",
"event_date": "2026-06-12",
"source_url": "https://www.fiercebiotech.com/pharma/novo-reports-cybersecurity-breach-tells-clinical-trial-patients-remain-vigilant",
"source_type": "patent_db",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Published: Jun 11, 2026 12:45pm. Summary: As cybersecurity threats have proliferated across industries in recent years, biopharma companies have emerged as prominent targets, with intellectual property, patient data and other sensitive information at stake. Now, Novo Nordisk is the latest drug giant to report a data breach.",
"created_at": "2026-06-12T08:16:43.684523",
"payload": {
"claim_scope": "composition",
"patent_number": null
},
"published_at": "2026-06-12",
"updated_at": "2026-06-12",
"ingested_at": "2026-06-12T08:16:43.684507Z",
"source": "https://www.fiercebiotech.com/pharma/novo-reports-cybersecurity-breach-tells-clinical-trial-patients-remain-vigilant",
"timestamp": "2026-06-12T00:00:00Z",
"raw_text": "None. Published: Jun 11, 2026 12:45pm. Summary: As cybersecurity threats have proliferated across industries in recent years, biopharma companies have emerged as prominent targets, with intellectual property, patient data and other sensitive information at stake. Now, Novo Nordisk is the latest drug giant to report a data breach.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "low",
"evidence_type": "preclinical",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 2.0,
"quality_score": 0.17,
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 1.0,
"delta_days": 0
}
|
| ev-95057b88 | 2026-06-12 | 科研文献 | Broad | RNA | FierceBiotechFierceBiotech |
查看完整Payload{
"event_id": "ev-95057b88",
"event_type": "publication",
"event_subtype": "preclinical_data",
"event_date": "2026-06-12",
"source_url": "https://www.fiercebiotech.com/biotech/genentech-executes-another-round-layoffs-3-vps-axed",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Published: Jun 11, 2026 2:09pm. Summary: Genentech vice presidents Vishva Dixit, Man-Wah Tan and Todd McDevitt are among the casualties in another round of layoffs from the South San Francisco subsidiary of Roche. The departures are part of a restructuring of the Genentech Research and Early Development (gRED) group. The company did not reveal how many positions are being affected.",
"created_at": "2026-06-12T08:16:43.683039",
"payload": {
"publication_venue": "Unknown",
"title": "None. Published: Jun 11, 2026 2:09pm. Summary: Genentech vice presidents Vishva Dixit, Man-Wah Tan and Todd McDevitt are",
"key_finding": "None. Published: Jun 11, 2026 2:09pm. Summary: Genentech vice presidents Vishva Dixit, Man-Wah Tan and Todd McDevitt are among the casualties in another round of layoffs from the South San Francisco subsidiary of Roche. The departures are part of a restructuring of the Genentech "
},
"published_at": "2026-06-12",
"updated_at": "2026-06-12",
"ingested_at": "2026-06-12T08:16:43.683023Z",
"source": "https://www.fiercebiotech.com/biotech/genentech-executes-another-round-layoffs-3-vps-axed",
"timestamp": "2026-06-12T00:00:00Z",
"raw_text": "None. Published: Jun 11, 2026 2:09pm. Summary: Genentech vice presidents Vishva Dixit, Man-Wah Tan and Todd McDevitt are among the casualties in another round of layoffs from the South San Francisco subsidiary of Roche. The departures are part of a restructuring of the Genentech Research and Early Development (gRED) group. The company did not reveal how many positions are being affected.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "low",
"evidence_type": "preclinical",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 1.6,
"quality_score": 0.17,
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 1.0,
"delta_days": 0
}
|
| ev-63e2544d | 2026-06-12 | 科研文献 | Broad | RNA | FierceBiotechFierceBiotech |
查看完整Payload{
"event_id": "ev-63e2544d",
"event_type": "publication",
"event_subtype": "preclinical_data",
"event_date": "2026-06-12",
"source_url": "https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Published: Dec 23, 2025 10:11am. Summary: As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.",
"created_at": "2026-06-12T08:16:43.685253",
"payload": {
"publication_venue": "Unknown",
"title": "None. Published: Dec 23, 2025 10:11am. Summary: As always, if you know of layoffs occurring at a biotech, please reach o",
"key_finding": "None. Published: Dec 23, 2025 10:11am. Summary: As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team."
},
"published_at": "2026-06-12",
"updated_at": "2026-06-12",
"ingested_at": "2026-06-12T08:16:43.685238Z",
"source": "https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2026",
"timestamp": "2026-06-12T00:00:00Z",
"raw_text": "None. Published: Dec 23, 2025 10:11am. Summary: As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "low",
"evidence_type": "preclinical",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 1.6,
"quality_score": 0.17,
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 1.0,
"delta_days": 0
}
|
| ev-14d02ccd | 2026-06-12 | 专利布局 | Broad | RNA | FierceBiotechFierceBiotech |
查看完整Payload{
"event_id": "ev-14d02ccd",
"event_type": "patent",
"event_subtype": "application_filed",
"event_date": "2026-06-12",
"source_url": "https://www.fiercebiotech.com/pharma/not-simply-saving-cost-inside-astellas-ceo-5-year-strategy-counter-xtandi-patent-cliff",
"source_type": "patent_db",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Published: Jun 11, 2026 12:43pm. Summary: Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue decline with a 200 billion yen ($1.3 billion) cost-savings program anchored in its new five-year strategic plan. But to CEO Naoki Okamura, “it’s not simply saving the cost or reducing the headcount.” ",
"created_at": "2026-06-12T08:16:43.682259",
"payload": {
"claim_scope": "composition",
"patent_number": null
},
"published_at": "2026-06-12",
"updated_at": "2026-06-12",
"ingested_at": "2026-06-12T08:16:43.682245Z",
"source": "https://www.fiercebiotech.com/pharma/not-simply-saving-cost-inside-astellas-ceo-5-year-strategy-counter-xtandi-patent-cliff",
"timestamp": "2026-06-12T00:00:00Z",
"raw_text": "None. Published: Jun 11, 2026 12:43pm. Summary: Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue decline with a 200 billion yen ($1.3 billion) cost-savings program anchored in its new five-year strategic plan. But to CEO Naoki Okamura, “it’s not simply saving the cost or reducing the headcount.” ",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "low",
"evidence_type": "preclinical",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 2.0,
"quality_score": 0.17,
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 1.0,
"delta_days": 0
}
|
| ev-0f764c8a | 2026-06-12 | 专利布局 | Broad | RNA | FierceBiotechFierceBiotech |
查看完整Payload{
"event_id": "ev-0f764c8a",
"event_type": "patent",
"event_subtype": "application_filed",
"event_date": "2026-06-12",
"source_url": "https://www.fiercebiotech.com/ai-and-machine-learning/all-hhs-agencies-saw-ai-use-case-increases-fy-2025-bipartisan-policy-center",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Published: Jun 11, 2026 1:05pm. Summary: There was a big uptick in the use of AI across all HHS agencies in 2025, though analysts note some use cases may “reflect new reporting requirements instead of new deployments.\"",
"created_at": "2026-06-12T08:16:43.683789",
"payload": {
"claim_scope": "composition",
"patent_number": null
},
"published_at": "2026-06-12",
"updated_at": "2026-06-12",
"ingested_at": "2026-06-12T08:16:43.683773Z",
"source": "https://www.fiercebiotech.com/ai-and-machine-learning/all-hhs-agencies-saw-ai-use-case-increases-fy-2025-bipartisan-policy-center",
"timestamp": "2026-06-12T00:00:00Z",
"raw_text": "None. Published: Jun 11, 2026 1:05pm. Summary: There was a big uptick in the use of AI across all HHS agencies in 2025, though analysts note some use cases may “reflect new reporting requirements instead of new deployments.\"",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "low",
"evidence_type": "preclinical",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 1.6,
"quality_score": 0.17,
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 1.0,
"delta_days": 0
}
|
| ev-fa44c3a2 | 2026-06-11 | 临床研究 | Broad | RNA | Endpoints新闻Endpoints News |
查看完整Payload{
"event_id": "ev-fa44c3a2",
"event_type": "clinical",
"event_subtype": "IND_filing",
"event_date": "2026-06-11",
"source_url": "https://endpoints.news/the-seeming-inevitability-of-rising-healthcare-costs/",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "The seeming inevitability of rising healthcare costs. Published: Thu, 11 Jun 2026 17:53:09 +0000. Summary: We’re getting our first signs of where healthcare costs are heading next year.\n\n According to a survey of actuaries at 27 health plans covering employers and individuals on the exchanges",
"created_at": "2026-06-12T08:16:43.694633",
"payload": {
"drug_name": null,
"indication_id": null,
"phase": "phase1",
"trial_id": "NCT00000000"
},
"published_at": "2026-06-11",
"updated_at": "2026-06-11",
"ingested_at": "2026-06-12T08:16:43.694613Z",
"source": "https://endpoints.news/the-seeming-inevitability-of-rising-healthcare-costs/",
"timestamp": "2026-06-11T00:00:00Z",
"raw_text": "The seeming inevitability of rising healthcare costs. Published: Thu, 11 Jun 2026 17:53:09 +0000. Summary: We’re getting our first signs of where healthcare costs are heading next year.\n\n According to a survey of actuaries at 27 health plans covering employers and individuals on the exchanges",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "clinical_human",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 5.6,
"quality_score": 0.17,
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.995,
"delta_days": 1
}
|
| ev-c1c782e1 | 2026-06-11 | 专利布局 | Broad | RNA | Endpoints新闻Endpoints News |
查看完整Payload{
"event_id": "ev-c1c782e1",
"event_type": "patent",
"event_subtype": "application_filed",
"event_date": "2026-06-11",
"source_url": "https://endpoints.news/drugmakers-are-turning-to-logistics-providers-as-trade-disruptions-linger-dhl-exec-says/",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "Drugmakers are turning to logistics providers as trade disruptions linger, DHL exec says. Published: Thu, 11 Jun 2026 15:30:23 +0000. Summary: DHL is in discussions with multiple major drugmakers who are looking for the logistics company to either take over their sites or access its resources, the company’s supply chain business CEO Hendrik Venter says.\n\n\n\n Pharma ...",
"created_at": "2026-06-12T08:16:43.695440",
"payload": {
"claim_scope": "composition",
"patent_number": null
},
"published_at": "2026-06-11",
"updated_at": "2026-06-11",
"ingested_at": "2026-06-12T08:16:43.695422Z",
"source": "https://endpoints.news/drugmakers-are-turning-to-logistics-providers-as-trade-disruptions-linger-dhl-exec-says/",
"timestamp": "2026-06-11T00:00:00Z",
"raw_text": "Drugmakers are turning to logistics providers as trade disruptions linger, DHL exec says. Published: Thu, 11 Jun 2026 15:30:23 +0000. Summary: DHL is in discussions with multiple major drugmakers who are looking for the logistics company to either take over their sites or access its resources, the company’s supply chain business CEO Hendrik Venter says.\n\n\n\n Pharma ...",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "low",
"evidence_type": "preclinical",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 1.6,
"quality_score": 0.17,
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.995,
"delta_days": 1
}
|
| ev-53d2e248 | 2026-06-11 | 融资事件 | Broad | RNA | Endpoints新闻Endpoints News |
查看完整Payload{
"event_id": "ev-53d2e248",
"event_type": "financing",
"event_subtype": "IPO",
"event_date": "2026-06-11",
"source_url": "https://endpoints.news/summit-withdraws-500m-offering-citing-market-conditions/",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "Summit withdraws $500M offering, citing 'market conditions'. Published: Thu, 11 Jun 2026 15:12:38 +0000. Summary: The current biotech environment can apparently support an industry-record IPO and simultaneously hamper efforts to raise half a billion dollars.\n\n Summit Therapeutics ditched plans for a $500 million public offering, the company disclosed in an ...",
"created_at": "2026-06-12T08:16:43.696250",
"payload": {
"amount_usd": 500000000.0,
"round_type": "IPO",
"lead_investor_ids": [],
"use_of_proceeds": null
},
"published_at": "2026-06-11",
"updated_at": "2026-06-11",
"ingested_at": "2026-06-12T08:16:43.696235Z",
"source": "https://endpoints.news/summit-withdraws-500m-offering-citing-market-conditions/",
"timestamp": "2026-06-11T00:00:00Z",
"raw_text": "Summit withdraws $500M offering, citing 'market conditions'. Published: Thu, 11 Jun 2026 15:12:38 +0000. Summary: The current biotech environment can apparently support an industry-record IPO and simultaneously hamper efforts to raise half a billion dollars.\n\n Summit Therapeutics ditched plans for a $500 million public offering, the company disclosed in an ...",
"strategic_tags": [
"mega_round"
],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "venture",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 4.8,
"quality_score": 0.2338,
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.995,
"delta_days": 1
}
|
| ev-50347837 | 2026-06-11 | FDA | Broad | RNA | Endpoints新闻Endpoints News |
查看完整Payload{
"event_id": "ev-50347837",
"event_type": "FDA",
"event_subtype": "CRL",
"event_date": "2026-06-11",
"source_url": "https://endpoints.news/camurus-second-crl-for-acromegaly-drug-teva-details-workforce-cuts/",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "Camurus’ second CRL for acromegaly drug; Teva details workforce cuts. Published: Thu, 11 Jun 2026 14:45:20 +0000. Summary: Plus, news about a drug shortages report and Axplora:\n\n 🛑 Camurus has been hit with a second CRL: The rejection is for the drug CAM2029 in acromegaly due to problems at a third-party manufacturer. The ...",
"created_at": "2026-06-12T08:16:43.716090",
"payload": {
"drug_name": null,
"designation_type": "CRL",
"regulatory_body": "FDA"
},
"published_at": "2026-06-11",
"updated_at": "2026-06-11",
"ingested_at": "2026-06-12T08:16:43.716071Z",
"source": "https://endpoints.news/camurus-second-crl-for-acromegaly-drug-teva-details-workforce-cuts/",
"timestamp": "2026-06-11T00:00:00Z",
"raw_text": "Camurus’ second CRL for acromegaly drug; Teva details workforce cuts. Published: Thu, 11 Jun 2026 14:45:20 +0000. Summary: Plus, news about a drug shortages report and Axplora:\n\n 🛑 Camurus has been hit with a second CRL: The rejection is for the drug CAM2029 in acromegaly due to problems at a third-party manufacturer. The ...",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "regulatory",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 5.6,
"quality_score": 0.17,
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.995,
"delta_days": 1
}
|
| ev-1d9093ee | 2026-06-11 | 科研文献 | Broad | RNA | Endpoints新闻Endpoints News |
查看完整Payload{
"event_id": "ev-1d9093ee",
"event_type": "publication",
"event_subtype": "preclinical_data",
"event_date": "2026-06-11",
"source_url": "https://endpoints.news/sensorion-axes-hearing-loss-program-novartis-biomarker-data-in-muscular-dystrophy/",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy. Published: Thu, 11 Jun 2026 14:48:47 +0000. Summary: Plus, news about Imaavy. \n\n 👂 Sensorion selects one hearing loss program, axes another: The biotech is ending the development of SENS-501 for OTOF-related hearing loss following a “strategic review.” As ...",
"created_at": "2026-06-12T08:16:43.715177",
"payload": {
"publication_venue": "Unknown",
"title": "Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy. Published: Thu, 11 Jun 2026 14:48:4",
"key_finding": "Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy. Published: Thu, 11 Jun 2026 14:48:47 +0000. Summary: Plus, news about Imaavy. \n\n 👂 Sensorion selects one hearing loss program, axes another: The biotech is ending the development of SENS-501 for "
},
"published_at": "2026-06-11",
"updated_at": "2026-06-11",
"ingested_at": "2026-06-12T08:16:43.715153Z",
"source": "https://endpoints.news/sensorion-axes-hearing-loss-program-novartis-biomarker-data-in-muscular-dystrophy/",
"timestamp": "2026-06-11T00:00:00Z",
"raw_text": "Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophy. Published: Thu, 11 Jun 2026 14:48:47 +0000. Summary: Plus, news about Imaavy. \n\n 👂 Sensorion selects one hearing loss program, axes another: The biotech is ending the development of SENS-501 for OTOF-related hearing loss following a “strategic review.” As ...",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "low",
"evidence_type": "animal",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 0.8,
"quality_score": 0.2338,
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.995,
"delta_days": 1
}
|
| ev-7324eb0c | 2026-06-10 | 科研文献 | Broad | RNA | PubMed文献PubMed / NCBI |
查看完整Payload{
"event_id": "ev-7324eb0c",
"event_type": "publication",
"event_subtype": "preclinical_data",
"event_date": "2026-06-10",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/42263201/",
"source_type": "pubmed",
"company_ids": [],
"confidence": 0.9,
"raw_text_snippet": "Landmark paper published in ACS Sens showing: Modular CRISPR-Cas12a-Activated Gold Nanoparticle Assay for Rapid Visual Detection of Hepatocellular Carcinoma-Related miRNAs.",
"created_at": "2026-06-10T01:09:33.945107",
"payload": {
"publication_venue": "Unknown",
"title": "Landmark paper published in ACS Sens showing: Modular CRISPR-Cas12a-Activated Gold Nanoparticle Assay for Rapid Visual D",
"key_finding": "Landmark paper published in ACS Sens showing: Modular CRISPR-Cas12a-Activated Gold Nanoparticle Assay for Rapid Visual Detection of Hepatocellular Carcinoma-Related miRNAs."
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.945088Z",
"source": "https://pubmed.ncbi.nlm.nih.gov/42263201/",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "Landmark paper published in ACS Sens showing: Modular CRISPR-Cas12a-Activated Gold Nanoparticle Assay for Rapid Visual Detection of Hepatocellular Carcinoma-Related miRNAs.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "low",
"evidence_type": "preclinical",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 1.8,
"quality_score": 0.4703,
"source_name": "PubMed",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-f5632dac | 2026-06-10 | 临床研究 | Broad | RNA | 生物谷生物谷 |
查看完整Payload{
"event_id": "ev-f5632dac",
"event_type": "clinical",
"event_subtype": "IND_filing",
"event_date": "2026-06-10",
"source_url": "http://news.bioon.com/article/c0cd9393393f.html",
"source_type": "news",
"company_ids": [],
"confidence": 0.88,
"raw_text_snippet": "Nat Commun：爆红减重针再破圈！司美格鲁肽或可放缓人体表观遗传衰老！. 来源报道正文:",
"created_at": "2026-06-10T01:09:33.989623",
"payload": {
"drug_name": null,
"indication_id": null,
"phase": "phase1",
"trial_id": "NCT00000000"
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.989607Z",
"source": "http://news.bioon.com/article/c0cd9393393f.html",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "Nat Commun：爆红减重针再破圈！司美格鲁肽或可放缓人体表观遗传衰老！. 来源报道正文:",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "clinical_human",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 5.6,
"quality_score": 0.363,
"source_name": "生物谷",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-ffef4c6d | 2026-06-10 | 融资事件 | Broad | RNA | FierceBiotechFierceBiotech |
查看完整Payload{
"event_id": "ev-ffef4c6d",
"event_type": "financing",
"event_subtype": "IPO",
"event_date": "2026-06-10",
"source_url": "https://www.fiercebiotech.com/biotech/fueled-ma-and-partnerships-biotech-poised-continued-growth-ey",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Summary: Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum into 2026, as the volume and value of licensing and M&A deals continues to increase. New IPOs and the recovery of venture capital funding are helping, as well.",
"created_at": "2026-06-10T01:09:33.946142",
"payload": {
"amount_usd": 0.0,
"round_type": "IPO",
"lead_investor_ids": [],
"use_of_proceeds": null
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.946125Z",
"source": "https://www.fiercebiotech.com/biotech/fueled-ma-and-partnerships-biotech-poised-continued-growth-ey",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "None. Summary: Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum into 2026, as the volume and value of licensing and M&A deals continues to increase. New IPOs and the recovery of venture capital funding are helping, as well.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "venture",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 4.8,
"quality_score": 0.374,
"source_name": "FierceBiotech",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-f5f3b7f0 | 2026-06-10 | 融资事件 | Broad | RNA | fiercepharma.comfiercepharma.com |
查看完整Payload{
"event_id": "ev-f5f3b7f0",
"event_type": "financing",
"event_subtype": "series_a",
"event_date": "2026-06-10",
"source_url": "https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Summary: Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.",
"created_at": "2026-06-10T01:09:33.968487",
"payload": {
"amount_usd": 0.0,
"round_type": "series_a",
"lead_investor_ids": [],
"use_of_proceeds": null
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.968471Z",
"source": "https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "None. Summary: Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "venture",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 4.8,
"quality_score": 0.272,
"source_name": "FiercePharma",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-e5fb7239 | 2026-06-10 | 融资事件 | Broad | RNA | FierceBiotechFierceBiotech |
查看完整Payload{
"event_id": "ev-e5fb7239",
"event_type": "financing",
"event_subtype": "IPO",
"event_date": "2026-06-10",
"source_url": "https://www.fiercebiotech.com/biotech/cancer-biotech-parabilis-ups-ipo-plans-potentially-record-setting-637m",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Summary: Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, with a whopping $625 million, Parabilis Medicines has upsized its own IPO plans with the potential to eclipse that record.",
"created_at": "2026-06-10T01:09:33.947001",
"payload": {
"amount_usd": 625000000.0,
"round_type": "IPO",
"lead_investor_ids": [],
"use_of_proceeds": null
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.946984Z",
"source": "https://www.fiercebiotech.com/biotech/cancer-biotech-parabilis-ups-ipo-plans-potentially-record-setting-637m",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "None. Summary: Mere months after obesity biotech Kailera Therapeutics netted the biggest initial public offering the sector has ever seen, with a whopping $625 million, Parabilis Medicines has upsized its own IPO plans with the potential to eclipse that record.",
"strategic_tags": [
"mega_round"
],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "venture",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 4.8,
"quality_score": 0.374,
"source_name": "FierceBiotech",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-dded0bd3 | 2026-06-10 | 临床研究 | Broad | RNA | FierceBiotechFierceBiotech |
查看完整Payload{
"event_id": "ev-dded0bd3",
"event_type": "clinical",
"event_subtype": "trial_start",
"event_date": "2026-06-10",
"source_url": "https://www.fiercebiotech.com/biotech/ada-astrazenecas-oral-glp-1-shows-competitive-efficacy-standard-tolerability-phase-2",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Summary: With a pair of phase 2 readouts, AstraZeneca is positioning itself to potentially capture a portion of the oral GLP-1 market. Up next, its elecoglipron is heading into pivotal studies.",
"created_at": "2026-06-10T01:09:33.963517",
"payload": {
"drug_name": "AstraZeneca",
"indication_id": null,
"phase": "phase2",
"trial_id": "NCT00000000"
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.963498Z",
"source": "https://www.fiercebiotech.com/biotech/ada-astrazenecas-oral-glp-1-shows-competitive-efficacy-standard-tolerability-phase-2",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "None. Summary: With a pair of phase 2 readouts, AstraZeneca is positioning itself to potentially capture a portion of the oral GLP-1 market. Up next, its elecoglipron is heading into pivotal studies.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "clinical_human",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 5.6,
"quality_score": 0.272,
"source_name": "FierceBiotech",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-d6426e2d | 2026-06-10 | 科研文献 | Broad | RNA | FierceBiotechFierceBiotech |
查看完整Payload{
"event_id": "ev-d6426e2d",
"event_type": "publication",
"event_subtype": "preclinical_data",
"event_date": "2026-06-10",
"source_url": "https://www.fiercebiotech.com/biotech/gsk-inks-106b-nuvalent-buyout-challenge-roche-and-pfizer-lung-cancer",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Summary: GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that could challenge products from Roche, Pfizer and other drugmakers. ",
"created_at": "2026-06-10T01:09:33.966608",
"payload": {
"publication_venue": "Unknown",
"title": "None. Summary: GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that",
"key_finding": "None. Summary: GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that could challenge products from Roche, Pfizer and other drugmakers. "
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.966594Z",
"source": "https://www.fiercebiotech.com/biotech/gsk-inks-106b-nuvalent-buyout-challenge-roche-and-pfizer-lung-cancer",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "None. Summary: GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that could challenge products from Roche, Pfizer and other drugmakers. ",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "low",
"evidence_type": "preclinical",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 1.6,
"quality_score": 0.272,
"source_name": "FierceBiotech",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-c2de1e2e | 2026-06-10 | licensing | Broad | RNA | FierceBiotechFierceBiotech |
查看完整Payload{
"event_id": "ev-c2de1e2e",
"event_type": "licensing",
"event_subtype": "in_license",
"event_date": "2026-06-10",
"source_url": "https://www.fiercebiotech.com/biotech/lilly-licenses-alzecure-alzheimers-asset-1b-biobucks",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Summary: Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease from AlzeCure Pharma for up to $1 billion biobucks.",
"created_at": "2026-06-10T01:09:33.955501",
"payload": {
"licensor_company_id": "",
"licensee_company_id": "",
"asset_type": "platform",
"total_deal_value_usd": 1000000000.0
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.955482Z",
"source": "https://www.fiercebiotech.com/biotech/lilly-licenses-alzecure-alzheimers-asset-1b-biobucks",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "None. Summary: Eli Lilly has signed a heavily backloaded agreement to license a gamma-secretase modulator treatment for Alzheimer's disease from AlzeCure Pharma for up to $1 billion biobucks.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "corporate",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 4.8,
"quality_score": 0.374,
"source_name": "FierceBiotech",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-bb26d80c | 2026-06-10 | 融资事件 | Broad | RNA | FierceBiotechFierceBiotech |
查看完整Payload{
"event_id": "ev-bb26d80c",
"event_type": "financing",
"event_subtype": "series_a",
"event_date": "2026-06-10",
"source_url": "https://www.fiercebiotech.com/medtech/cequr-nabs-100m-series-e-boost-commercial-operations-its-insulin-delivery-patch",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Summary: Swiss medtech CeQur has raised $100 million in a series E funding round for what it called its “most ambitious phase of commercial growth.”",
"created_at": "2026-06-10T01:09:33.964322",
"payload": {
"amount_usd": 100000000.0,
"round_type": "series_a",
"lead_investor_ids": [],
"use_of_proceeds": null
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.964299Z",
"source": "https://www.fiercebiotech.com/medtech/cequr-nabs-100m-series-e-boost-commercial-operations-its-insulin-delivery-patch",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "None. Summary: Swiss medtech CeQur has raised $100 million in a series E funding round for what it called its “most ambitious phase of commercial growth.”",
"strategic_tags": [
"mega_round"
],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "venture",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 4.8,
"quality_score": 0.374,
"source_name": "FierceBiotech",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-b3a6ab2a | 2026-06-10 | FDA | Broad | RNA | fiercepharma.comfiercepharma.com |
查看完整Payload{
"event_id": "ev-b3a6ab2a",
"event_type": "FDA",
"event_subtype": "fast_track",
"event_date": "2026-06-10",
"source_url": "https://www.fiercepharma.com/pharma/pfizer-scores-fda-pediatric-expansion-hemophilia-treatment-hympavzi",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Summary: The FDA has expanded the label for Pfizer’s Hympavzi, now including patients age 6 and older who have hemophilia A or B. The new expansion covers all patients 6 and older, regardless of their inhibitor status. The new nod also opens up the treatment to those 12 and older who have developed inhibitors.",
"created_at": "2026-06-10T01:09:33.979130",
"payload": {
"drug_name": null,
"designation_type": "fast_track",
"regulatory_body": "FDA"
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.979114Z",
"source": "https://www.fiercepharma.com/pharma/pfizer-scores-fda-pediatric-expansion-hemophilia-treatment-hympavzi",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "None. Summary: The FDA has expanded the label for Pfizer’s Hympavzi, now including patients age 6 and older who have hemophilia A or B. The new expansion covers all patients 6 and older, regardless of their inhibitor status. The new nod also opens up the treatment to those 12 and older who have developed inhibitors.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "regulatory",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 5.6,
"quality_score": 0.272,
"source_name": "FiercePharma",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-b085df1e | 2026-06-10 | FDA | Broad | RNA | fiercepharma.comfiercepharma.com |
查看完整Payload{
"event_id": "ev-b085df1e",
"event_type": "FDA",
"event_subtype": "NDA_submission",
"event_date": "2026-06-10",
"source_url": "https://www.fiercepharma.com/pharma/ada-lilly-posts-oral-semaglutide-topping-data-foundayo-speeds-toward-2nd-potential-nod",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Summary: With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into Type 2 diabetes.",
"created_at": "2026-06-10T01:09:33.976642",
"payload": {
"drug_name": null,
"designation_type": "NDA_submission",
"regulatory_body": "FDA"
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.976623Z",
"source": "https://www.fiercepharma.com/pharma/ada-lilly-posts-oral-semaglutide-topping-data-foundayo-speeds-toward-2nd-potential-nod",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "None. Summary: With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into Type 2 diabetes.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "regulatory",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 5.6,
"quality_score": 0.272,
"source_name": "FiercePharma",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-66c43188 | 2026-06-10 | 科研文献 | Broad | RNA | FierceBiotechFierceBiotech |
查看完整Payload{
"event_id": "ev-66c43188",
"event_type": "publication",
"event_subtype": "preclinical_data",
"event_date": "2026-06-10",
"source_url": "https://www.fiercebiotech.com/medtech/roche-will-continue-eu600m-diagnostics-investment-germany-warns-future-risk",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Summary: As news hit last week that Eli Lilly and Boehringer Ingelheim are cutting investments in Germany, Roche said it will not be following suit—for now.",
"created_at": "2026-06-10T01:09:33.965086",
"payload": {
"publication_venue": "Unknown",
"title": "None. Summary: As news hit last week that Eli Lilly and Boehringer Ingelheim are cutting investments in Germany, Roche s",
"key_finding": "None. Summary: As news hit last week that Eli Lilly and Boehringer Ingelheim are cutting investments in Germany, Roche said it will not be following suit—for now."
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.965070Z",
"source": "https://www.fiercebiotech.com/medtech/roche-will-continue-eu600m-diagnostics-investment-germany-warns-future-risk",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "None. Summary: As news hit last week that Eli Lilly and Boehringer Ingelheim are cutting investments in Germany, Roche said it will not be following suit—for now.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "low",
"evidence_type": "preclinical",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 1.6,
"quality_score": 0.272,
"source_name": "FierceBiotech",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-28b4c99c | 2026-06-10 | 融资事件 | Broad | RNA | fiercepharma.comfiercepharma.com |
查看完整Payload{
"event_id": "ev-28b4c99c",
"event_type": "financing",
"event_subtype": "series_a",
"event_date": "2026-06-10",
"source_url": "https://www.fiercepharma.com/pharma/ada-lilly-widening-its-lead-obesity-race-analyst",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Summary: Eli Lilly emerged as the “clear winner from ADA,” according to RBC Capital Markets analyst Trung Hyunh, who added that “the field is getting more crowded—but Lilly is widening its lead.”",
"created_at": "2026-06-10T01:09:33.977402",
"payload": {
"amount_usd": 0.0,
"round_type": "series_a",
"lead_investor_ids": [],
"use_of_proceeds": null
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.977385Z",
"source": "https://www.fiercepharma.com/pharma/ada-lilly-widening-its-lead-obesity-race-analyst",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "None. Summary: Eli Lilly emerged as the “clear winner from ADA,” according to RBC Capital Markets analyst Trung Hyunh, who added that “the field is getting more crowded—but Lilly is widening its lead.”",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "venture",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 4.8,
"quality_score": 0.272,
"source_name": "FiercePharma",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-288789ec | 2026-06-10 | 临床研究 | Broad | RNA | FierceBiotechFierceBiotech |
查看完整Payload{
"event_id": "ev-288789ec",
"event_type": "clinical",
"event_subtype": "trial_start",
"event_date": "2026-06-10",
"source_url": "https://www.fiercebiotech.com/biotech/bial-bails-after-parkinsons-fail-axing-asset-over-phase-2-miss",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "None. Summary: Bial has stopped development in a subpopulation of Parkinson’s disease patients after its phase 2b trial missed its primary and key secondary efficacy endpoints. ",
"created_at": "2026-06-10T01:09:33.965899",
"payload": {
"drug_name": null,
"indication_id": null,
"phase": "phase2",
"trial_id": "NCT00000000"
},
"published_at": "2026-06-10",
"updated_at": "2026-06-10",
"ingested_at": "2026-06-10T01:09:33.965873Z",
"source": "https://www.fiercebiotech.com/biotech/bial-bails-after-parkinsons-fail-axing-asset-over-phase-2-miss",
"timestamp": "2026-06-10T00:00:00Z",
"raw_text": "None. Summary: Bial has stopped development in a subpopulation of Parkinson’s disease patients after its phase 2b trial missed its primary and key secondary efficacy endpoints. ",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "clinical_human",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 5.6,
"quality_score": 0.272,
"source_name": "FierceBiotech",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.99,
"delta_days": 2
}
|
| ev-92e4355b | 2026-06-09 | 融资事件 | Broad | RNA | BioPharma报道BioPharma Dive |
查看完整Payload{
"event_id": "ev-92e4355b",
"event_type": "financing",
"event_subtype": "IPO",
"event_date": "2026-06-09",
"source_url": "https://www.biopharmadive.com/news/gsk-nuvalent-11B-dollar-acquisition-alk-ros1/822340/",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "GSK boosts cancer pipeline with $11B Nuvalent buyout. Summary: The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.",
"created_at": "2026-06-10T01:09:33.983845",
"payload": {
"amount_usd": 11000000000.0,
"round_type": "IPO",
"lead_investor_ids": [],
"use_of_proceeds": null
},
"published_at": "2026-06-09",
"updated_at": "2026-06-09",
"ingested_at": "2026-06-10T01:09:33.983829Z",
"source": "https://www.biopharmadive.com/news/gsk-nuvalent-11B-dollar-acquisition-alk-ros1/822340/",
"timestamp": "2026-06-09T00:00:00Z",
"raw_text": "GSK boosts cancer pipeline with $11B Nuvalent buyout. Summary: The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.",
"strategic_tags": [
"mega_round"
],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "venture",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 4.8,
"quality_score": 0.374,
"source_name": "BioPharma Dive",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.9851,
"delta_days": 3
}
|
| ev-871350ab | 2026-06-09 | 科研文献 | Broad | RNA | statnews.comstatnews.com |
查看完整Payload{
"event_id": "ev-871350ab",
"event_type": "publication",
"event_subtype": "preclinical_data",
"event_date": "2026-06-09",
"source_url": "https://www.statnews.com/pharmalot/2026/06/09/gsk-buying-nuvalent-cancer-drug-astrazeneca-obesity-pill-data/?utm_campaign=rss",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more. Summary: GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology",
"created_at": "2026-06-10T01:09:33.981802",
"payload": {
"publication_venue": "Unknown",
"title": "STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more. Summary: GSK a",
"key_finding": "STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more. Summary: GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology"
},
"published_at": "2026-06-09",
"updated_at": "2026-06-09",
"ingested_at": "2026-06-10T01:09:33.981786Z",
"source": "https://www.statnews.com/pharmalot/2026/06/09/gsk-buying-nuvalent-cancer-drug-astrazeneca-obesity-pill-data/?utm_campaign=rss",
"timestamp": "2026-06-09T00:00:00Z",
"raw_text": "STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more. Summary: GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "low",
"evidence_type": "preclinical",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 1.6,
"quality_score": 0.289,
"source_name": "STAT News",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.9851,
"delta_days": 3
}
|
| ev-69f4745e | 2026-06-09 | acquisition | Broad | RNA | statnews.comstatnews.com |
查看完整Payload{
"event_id": "ev-69f4745e",
"event_type": "acquisition",
"event_subtype": "full_acquisition",
"event_date": "2026-06-09",
"source_url": "https://www.statnews.com/2026/06/09/biotech-news-gilead-and-merck-latest-trial-success-and-flop/?utm_campaign=rss",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "Gilead and Merck’s latest trial success and flop. Summary: AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout",
"created_at": "2026-06-10T01:09:33.980983",
"payload": {
"acquirer_company_id": "",
"target_company_id": "",
"deal_value_usd": 10600000000.0
},
"published_at": "2026-06-09",
"updated_at": "2026-06-09",
"ingested_at": "2026-06-10T01:09:33.980968Z",
"source": "https://www.statnews.com/2026/06/09/biotech-news-gilead-and-merck-latest-trial-success-and-flop/?utm_campaign=rss",
"timestamp": "2026-06-09T00:00:00Z",
"raw_text": "Gilead and Merck’s latest trial success and flop. Summary: AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "venture",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 4.8,
"quality_score": 0.3974,
"source_name": "STAT News",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.9851,
"delta_days": 3
}
|
| ev-5aa643dd | 2026-06-09 | 临床研究 | Broad | RNA | BioPharma报道BioPharma Dive |
查看完整Payload{
"event_id": "ev-5aa643dd",
"event_type": "clinical",
"event_subtype": "IND_filing",
"event_date": "2026-06-09",
"source_url": "https://www.biopharmadive.com/news/treeline-reverse-merger-standard-biotools-cancer-drugs/822352/",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "Stealthy startup Treeline plans a reverse merger. Summary: Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.",
"created_at": "2026-06-10T01:09:33.982874",
"payload": {
"drug_name": null,
"indication_id": null,
"phase": "phase1",
"trial_id": "NCT00000000"
},
"published_at": "2026-06-09",
"updated_at": "2026-06-09",
"ingested_at": "2026-06-10T01:09:33.982858Z",
"source": "https://www.biopharmadive.com/news/treeline-reverse-merger-standard-biotools-cancer-drugs/822352/",
"timestamp": "2026-06-09T00:00:00Z",
"raw_text": "Stealthy startup Treeline plans a reverse merger. Summary: Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "clinical_human",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 5.6,
"quality_score": 0.374,
"source_name": "BioPharma Dive",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.9851,
"delta_days": 3
}
|
| ev-0095da2e | 2026-06-09 | 临床研究 | Broad | RNA | statnews.comstatnews.com |
查看完整Payload{
"event_id": "ev-0095da2e",
"event_type": "clinical",
"event_subtype": "IND_filing",
"event_date": "2026-06-09",
"source_url": "https://www.statnews.com/pharmalot/2026/06/09/drug-shortages-systemic-problem-analysis/?utm_campaign=rss",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "STAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds. Summary: The number of prescription drug shortages in the U.S. fell by 23% last year, but a new analysis found other troubling signs about medicines in short supply.",
"created_at": "2026-06-10T01:09:33.979988",
"payload": {
"drug_name": null,
"indication_id": null,
"phase": "phase1",
"trial_id": "NCT00000000"
},
"published_at": "2026-06-09",
"updated_at": "2026-06-09",
"ingested_at": "2026-06-10T01:09:33.979972Z",
"source": "https://www.statnews.com/pharmalot/2026/06/09/drug-shortages-systemic-problem-analysis/?utm_campaign=rss",
"timestamp": "2026-06-09T00:00:00Z",
"raw_text": "STAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds. Summary: The number of prescription drug shortages in the U.S. fell by 23% last year, but a new analysis found other troubling signs about medicines in short supply.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "clinical_human",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 5.6,
"quality_score": 0.289,
"source_name": "STAT News",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.9851,
"delta_days": 3
}
|
| ev-9db5c1e6 | 2026-06-08 | 临床研究 | Moderna | mRNA (信使RNA) | 临床数据库ClinicalTrials.gov |
查看完整Payload{
"event_id": "ev-9db5c1e6",
"event_type": "clinical",
"event_subtype": "IND_filing",
"event_date": "2026-06-08",
"source_url": "https://clinicaltrials.gov/study/NCT07390474",
"source_type": "clinicaltrials",
"company_ids": [
"co-moderna"
],
"confidence": 0.95,
"raw_text_snippet": "Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV. Sponsor: National Institute of Allergy and Infectious Diseases (NIAID). Description: This is a phase 1, multicenter, open-label, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of DV201P-RNA and DV202B1-RNA, immunogens designed to induce HIV-1 envelope (Env) V2 apex-specific broadly neutralizing antibodies ",
"created_at": "2026-06-10T01:34:23.945586",
"payload": {
"drug_name": "HIV-1",
"indication_id": null,
"phase": "phase1",
"trial_id": "NCT00000000",
"modality_id": "mo-mrna",
"delivery_id": "de-lnp"
},
"published_at": "2026-01-29",
"updated_at": "2026-06-08",
"ingested_at": "2026-06-10T01:34:23.945552Z",
"source": "https://clinicaltrials.gov/study/NCT07390474",
"timestamp": "2026-06-08T00:00:00Z",
"raw_text": "Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV. Sponsor: National Institute of Allergy and Infectious Diseases (NIAID). Description: This is a phase 1, multicenter, open-label, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of DV201P-RNA and DV202B1-RNA, immunogens designed to induce HIV-1 envelope (Env) V2 apex-specific broadly neutralizing antibodies (V2 apex bnAbs). Both vaccines consist of a modified mRNA encapsulated in lipid nanoparticles (LNP) that when translated in cells produces HIV-1 Env gp150 transmembrane trimers. The trial will enroll adult volunteers without HIV and in overall good health.. Conditions: HIV",
"strategic_tags": [
"lnp"
],
"signal_candidates": [],
"industry_impact": "high",
"evidence_type": "clinical_human",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 7.7,
"quality_score": 1.0,
"source_name": "ClinicalTrials.gov",
"company": "Moderna",
"modality": "mRNA",
"delivery_system": "LNP (lipid nanoparticles)",
"entities": {
"company_ids": [
"co-moderna"
],
"modality_ids": [
"mo-mrna"
],
"delivery_ids": [
"de-lnp"
],
"indication_ids": []
},
"decay_weight": 0.9802,
"delta_days": 4
}
|
| ev-e181d624 | 2026-06-08 | 商业合作 | Broad | RNA | BioPharma报道BioPharma Dive |
查看完整Payload{
"event_id": "ev-e181d624",
"event_type": "partnership",
"event_subtype": "research_collab",
"event_date": "2026-06-08",
"source_url": "https://www.biopharmadive.com/news/roche-nurix-protein-degrader-btk-bexobrutideg-deal/822230/",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "Roche stakes $700M on Nurix’s protein-degrading drug. Summary: Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.",
"created_at": "2026-06-10T01:09:33.985845",
"payload": {
"partnership_scope": "Roche stakes $700M on Nurix’s protein-degrading drug. Summary: Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove"
},
"published_at": "2026-06-08",
"updated_at": "2026-06-08",
"ingested_at": "2026-06-10T01:09:33.985828Z",
"source": "https://www.biopharmadive.com/news/roche-nurix-protein-degrader-btk-bexobrutideg-deal/822230/",
"timestamp": "2026-06-08T00:00:00Z",
"raw_text": "Roche stakes $700M on Nurix’s protein-degrading drug. Summary: Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "corporate",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 4.8,
"quality_score": 0.374,
"source_name": "BioPharma Dive",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.9802,
"delta_days": 4
}
|
| ev-19e8304c | 2026-06-08 | 专利布局 | Alnylam | RNA | BioPharma报道BioPharma Dive |
查看完整Payload{
"event_id": "ev-19e8304c",
"event_type": "patent",
"event_subtype": "application_filed",
"event_date": "2026-06-08",
"source_url": "https://www.biopharmadive.com/news/city-therapeutics-rnai-series-b/822266/",
"source_type": "news",
"company_ids": [
"co-alnylam"
],
"confidence": 0.85,
"raw_text_snippet": "City banks nearly $100M for next-gen RNAi drugs. Summary: Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.",
"created_at": "2026-06-10T01:09:33.984882",
"payload": {
"claim_scope": "composition",
"patent_number": null
},
"published_at": "2026-06-08",
"updated_at": "2026-06-08",
"ingested_at": "2026-06-10T01:09:33.984867Z",
"source": "https://www.biopharmadive.com/news/city-therapeutics-rnai-series-b/822266/",
"timestamp": "2026-06-08T00:00:00Z",
"raw_text": "City banks nearly $100M for next-gen RNAi drugs. Summary: Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "low",
"evidence_type": "preclinical",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 1.6,
"quality_score": 0.3808,
"source_name": "BioPharma Dive",
"company": "Alnylam",
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [
"co-alnylam"
],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.9802,
"delta_days": 4
}
|
| ev-0e07965c | 2026-06-08 | FDA | Broad | RNA | BioPharma报道BioPharma Dive |
查看完整Payload{
"event_id": "ev-0e07965c",
"event_type": "FDA",
"event_subtype": "NDA_submission",
"event_date": "2026-06-08",
"source_url": "https://www.biopharmadive.com/news/ada-2026-lilly-retatrutide-pfizer-berobenatide-roche-enicepatide/822208/",
"source_type": "news",
"company_ids": [],
"confidence": 0.85,
"raw_text_snippet": "ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option. Summary: At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.",
"created_at": "2026-06-10T01:09:33.987053",
"payload": {
"drug_name": null,
"designation_type": "NDA_submission",
"regulatory_body": "FDA"
},
"published_at": "2026-06-08",
"updated_at": "2026-06-08",
"ingested_at": "2026-06-10T01:09:33.987036Z",
"source": "https://www.biopharmadive.com/news/ada-2026-lilly-retatrutide-pfizer-berobenatide-roche-enicepatide/822208/",
"timestamp": "2026-06-08T00:00:00Z",
"raw_text": "ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option. Summary: At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "medium",
"evidence_type": "regulatory",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 5.6,
"quality_score": 0.272,
"source_name": "BioPharma Dive",
"company": null,
"modality": null,
"delivery_system": null,
"entities": {
"company_ids": [],
"modality_ids": [],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.9802,
"delta_days": 4
}
|
| ev-7e24f94b | 2026-06-05 | FDA | Moderna | mRNA (信使RNA) | 临床数据库ClinicalTrials.gov |
查看完整Payload{
"event_id": "ev-7e24f94b",
"event_type": "FDA",
"event_subtype": "NDA_submission",
"event_date": "2026-06-05",
"source_url": "https://clinicaltrials.gov/study/NCT06744205",
"source_type": "clinicaltrials",
"company_ids": [
"co-moderna"
],
"confidence": 0.95,
"raw_text_snippet": "A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older. Sponsor: Sanofi Pasteur, a Sanofi Company. Description: The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminid",
"created_at": "2026-06-10T01:34:23.950706",
"payload": {
"drug_name": null,
"designation_type": "NDA_submission",
"regulatory_body": "FDA",
"modality_id": "mo-mrna"
},
"published_at": "2024-12-16",
"updated_at": "2026-06-05",
"ingested_at": "2026-06-10T01:34:23.950682Z",
"source": "https://clinicaltrials.gov/study/NCT06744205",
"timestamp": "2026-06-05T00:00:00Z",
"raw_text": "A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older. Sponsor: Sanofi Pasteur, a Sanofi Company. Description: The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.. Conditions: Influenza, Healthy Volunteers",
"strategic_tags": [],
"signal_candidates": [],
"industry_impact": "high",
"evidence_type": "regulatory",
"temporal_relevance": 7,
"cross_source_match": false,
"extraction_method": "heuristic",
"evidence_strength": 7.7,
"quality_score": 1.0,
"source_name": "ClinicalTrials.gov",
"company": "Moderna",
"modality": "mRNA",
"delivery_system": null,
"entities": {
"company_ids": [
"co-moderna"
],
"modality_ids": [
"mo-mrna"
],
"delivery_ids": [],
"indication_ids": []
},
"decay_weight": 0.9656,
"delta_days": 7
}
|